LBI-HTA - Publications - Search - Year: 2017
Number of items: 34.

Fischer, S. and Stanak, M. (2017): Social Return on Investment: Outcomes, Methods, and Economic Parameters. HTA-Projektbericht 96.

Rosian, K. and Winkler, R. (2017): Psychotherapy - concepts, effect factors and a comparison of legal regulations in three German speaking countries. HTA-Projektbericht 93.

McGahan, L. (2017): Durvalumab (Imfinzi™) for the treatment of patients with stage III non-small-cell lung cancer after prior chemoradiotherapy. DSD: Horizon Scanning in Oncology 76.

Grössmann, N. (2017): Nivolumab (Opdivo®) for metastatic DNA mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC). DSD: Horizon Scanning in Oncology 75.

Finnish Medicines Agency (FIMEA), EUnetHTA and Norwegian Medicines Agency (NoMA), EUnetHTA (2017): Midostaurin with standard chemotherapy in FLT3-Positive Acute Myeloid Leukaemia. EUnetHTA report. DSD: Horizon Scanning in Oncology 74.

Robausch, M. and Emprechtinger, R. (2017): Percutaneous aortic valve replacement (TAVI) in Austria. Part 2: Data analysis. HTA-Projektbericht 95b.

Hawlik, K. and Stanak, M. (2017): Perinatal care at the threshold of viability; Part I: Systematic Analysis of Outcomes and Resource Needs for Neonatal Intensive Care Units to inform Healthcare Planning. HTA-Projektbericht 97a.

Stanak, M. and Hawlik, K. (2017): Perinatal Care at the threshold of viability Part II: Decision-making at the threshold of viability and ethical challenges at Neonatal Intensive Care Units (NICUs). HTA-Projektbericht 97b.

Grössmann, N. and Wolf, S. (2017): Horizon Scanning in Oncology 33rd Prioritisation – 4th quarter 2017. HSO: 33rd Prioritisation.

Haute Autorité de Santé (HAS), EUnetHTA and Autoridade Nacional do Medicamento e Productos de Saude (INFARMED), EUnetHTA (2017): Regorafenib indicated as monotherapy for the treatment of adult patients with hepatocellular carcinoma (HCC) who have previously been treated with sorafenib. EUnetHTA report. DSD: Horizon Scanning in Oncology 73.

Wolf, S. and Fischer, S. (2017): Transcatheter Aortic Valve Implantation Part I: A systematic review of health economic evaluations. HTA-Projektbericht 95a.

Grössmann, N. (2017): Abemaciclib (Verzenio®) in combination with fulvestrant for treatment of HR-positive, HER2-negative advanced breast cancer (ABC). DSD: Horizon Scanning in Oncology 72.

McGahan, L. (2017): Olaparib (Lynparza®) in patients with BRCA-mutated metastatic breast cancer. DSD: Horizon Scanning in Oncology 71.

Grössmann, N. and Wolf, S. (2017): Horizon Scanning in Oncology: Results of the 32nd Prioritisation – 3rd quarter 2017. HSO: 32nd Prioritisation.

Gregor-Patera, N. and Petersen, P. and Wild, C. (2017): Sponsoring of Patient Initiatives in Austria 2016. Update of the Systematic Analyses 2015 and 2014. Rapid Assessment 007b_2. Update 2017.

Semlitsch, T. and Posch, N. (2017): Leadless pacemakers for right ventricle pacing. Update 2017. Decision Support Document 97/ 1. Update 2017.

Erdös, J. and Ibargoyen Roteta, N. and Gutiérrez Ibarluzea, I. (2017): Repetitive transcranial magnetic stimulation for treatment-resistant major depression. Decision Support Document 107.

Petersen, P. and Wild, C. (2017): Sponsoring of Patientinitiatives in Austria 2015. Update of the Systematic Analysis 2014.. Rapid Assessment 007b_1. Update 2017.

McGahan, L. (2017): Ceritinib (Zykadia®) as first-line therapy for patients with advanced ALK-positive non-small cell lung cancer. DSD: Horizon Scanning in Oncology 69.

Grössmann, N. (2017): Pembrolizumab (Keytruda®) as second-line treatment for patients with advanced urothelial carcinoma (UC). DSD: Horizon Scanning in Oncology 70.

Gregor-Patera, N. and Wild, C. (2017): Research interests of Non-interventional studies (NIS) in Austria. Update of the systematic analysis. Rapid Rapid Assessment 007c. Update 2017.

Grössmann, N. and Wolf, S. (2017): Horizon Scanning in Oncology 31st Prioritisation – 2nd quarter 2017 . HSO: 31st Prioritisation.

McGahan, L. (2017): Atezolizumab (Tecentriq®) in previously treated non-small cell lung cancer (NSCLC). DSD: Horizon Scanning in Oncology 68.

Grössmann, N. and Wolf, S. (2017): Horizon Scanning in Oncology: Results of the 30th Prioritisation – 1st quarter 2017. HSO: 30th Prioritisation.

Stanak, M. and Hawlik, K. (2017): Electric stimulation therapy in patients with gastroesophageal reflux disease. Decision Support Document 104.

Semlitsch, T. and Posch, N. (2017): Percutaneous disc volume reduction with focus on chemonucleolysis. Update 2017. Decision Support Document 21/ 1. Update 2017.

Rosian, K. and Piso, B. (2017): Radiofrequency ablation for metastatic spinal lesions. Decision Support Document 108.

Vreugdenburg, Thomas and Wild, C. (2017): Prostate artery embolisation for benign prostatic hyperplasia. Decision Support Document 105.

Wolf, S. (2017): Ipilimumab (Yervoy®) in the adjuvant therapy for high-risk stage III cutaneous melanoma. DSD: Horizon Scanning in Oncology 67.

Hawlik, K. and Wild, C. (2017): Extracorporeal cytokine haemadsorption in patients with sepsis or SIRS. Decision Support Document 106.

Wolf, S. and Grössmann, N. (2017): Ribociclib in combination with letrozole for the first-line therapy of HR-positive, HER2-negative recurrent or metastatic breast cancer. DSD: Horizon Scanning in Oncology 65.

Grössmann, N. and Wolf, S. (2017): Neratinib for the treatment of patients with HER2-positive breast cancer after trastuzumab-based adjuvant therapy. DSD: Horizon Scanning in Oncology 66.

McGahan, L. (2017): Palbociclib (Ibrance®) in combination with fulvestrant for the treatment of hormone-receptor-positive, HER2-negative advanced or metastatic breast cancer. DSD: Horizon Scanning in Oncology 64.

Wild, C. and Blagojevic, S. and Petersen, P. (2017): Annual Report 2016.

This list was generated on Sun Oct 21 07:00:03 2018 CEST.